A Phase 3 interventional study of Rozanolixizumab in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 27 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.
Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 6th largest by enrollment, is the only one that started in 2023, is one of 7 in phase 3, and was the 5th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, China and 6 more countries
Ages 18+
By country, each count listing its studies:
rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 8 · Phase 4 1
First in 2017; this study’s year is marked. 1 started in 2023.
This study's enrollment of 62 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 67 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 17 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
18 studies in Myasthenia Gravis by UCB S.A.: 5 open now, 7 under way, 5 of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 12 in phase 3, and was the 9th registered.
UCB S.A.’s Myasthenia Gravis studies by the year they started, since 2017.
2 of the studies testing rozanolixizumab in Myasthenia Gravis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06540144Phase 3UCB Biopharma SRLAn Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | 2027-10-05 |
| NCT07246564UCB Biopharma SRLPhase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, from their registry updates:
Among UCB S.A.’s 18 in Myasthenia Gravis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.
Drug: Rozanolixizumab
Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.
Drug: Rozanolixizumab
Rozanolixizumab self-administration via Syringe Driver or Manual Push.
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 13 (Week 12)
Successful self-administration was defined by the participant (i) choosing the correct infusion site, (ii) administering SC, and (iii) delivering the intended dose.
Time frame: Week 12 (last dose of Self-administration Period 1)
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 19 (Week 18)
Successful Self-administration was defined by the participant (i) choosing the correct infusion site, (ii) administering SC, and (iii) delivering the intended dose.
Time frame: Week 18 (last dose of Self-administration Period 2)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26])
An Adverse Event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE starting on or after the date of first administration of rozanolixizumab in the study, up to and including 8 weeks (56 days) after the final dose.
Time frame: From Week 1 up to the End of Study Visit (Week 26)
Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods
The local site reactions up to 24 hours after each administration were defined as AEs reported as local site reactions as per case report form within one day after RLZ administration.
Time frame: Up to 24 hours after each administration during the Training Period (Baseline to Week 6) and Self-administration Periods (Week 7 to Week 18)
Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study
Medication errors were defined as an unintended failure in the drug treatment process that leads to, or has the potential to lead to, harm to the study participant. Medication Errors associated with adverse reactions during the 2 Self-administration Periods were measured.
Time frame: During the Self-administration Periods (Week 7 to Week 18)
The study started to enroll participants in April 2023 and concluded in April 2024.
| Milestone | All Participants: Training Period | Sequence 1: RLZ Syringe Driver (SRD) - RLZ Manual Push (MP) | Sequence 2: RLZ MP - RLZ SRD |
|---|---|---|---|
| Started | 62 | 0 | 0 |
| Completed | 55 | 0 | 0 |
| Not completed | 7 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 |
| Withdrew: Consent withdrawn by participant (not due to ae) | 1 | 0 | 0 |
| Withdrew: Not eligible for sa but continued in study | 3 | 0 | 0 |
| Milestone | All Participants: Training Period | Sequence 1: RLZ Syringe Driver (SRD) - RLZ Manual Push (MP) | Sequence 2: RLZ MP - RLZ SRD |
|---|---|---|---|
| Started | 0 | 28 | 27 |
| Completed | 0 | 23 | 26 |
| Not completed | 0 | 5 | 1 |
| Withdrew: Diagnosis change to amyotrophic lateral sclerosis | 0 | 1 | 0 |
| Withdrew: Consent withdrawn by participant (not due to ae) | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Participant became ineligible for sa | 0 | 1 | 0 |
| Withdrew: Missed infusion at visit 13, sa period1 incomplete | 0 | 2 | 0 |
| Milestone | All Participants: Training Period | Sequence 1: RLZ Syringe Driver (SRD) - RLZ Manual Push (MP) | Sequence 2: RLZ MP - RLZ SRD |
|---|---|---|---|
| Started | 0 | 25 | 26 |
| Completed | 0 | 25 | 26 |
| Not completed | 0 | 0 | 0 |
Successful self-administration was defined by the participant (i) choosing the correct infusion site, (ii) administering SC, and (iii) delivering the intended dose.
| percentage of participants | Period 1: RLZ SRD | Period 1: RLZ MP |
|---|---|---|
| Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 13 (Week 12) | 100 | 100 |
Successful Self-administration was defined by the participant (i) choosing the correct infusion site, (ii) administering SC, and (iii) delivering the intended dose.
| percentage of participants | Period 2: RLZ SRD | Period 2: RLZ MP |
|---|---|---|
| Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 19 (Week 18) | 100 | 100 |
An Adverse Event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE starting on or after the date of first administration of rozanolixizumab in the study, up to and including 8 weeks (56 days) after the final dose.
| percentage of participants | Period 1: RLZ SRD | Period 1: RLZ MP | Period 2: RLZ SRD | Period 2: RLZ MP | RLZ Total |
|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26]) | 35.7 | 29.6 | 26.9 | 38.5 | 75.8 |
The local site reactions up to 24 hours after each administration were defined as AEs reported as local site reactions as per case report form within one day after RLZ administration.
| percentage of participants | All Participants: Training Period | Period 1: RLZ SRD | Period 1: RLZ MP | Period 2: RLZ SRD | Period 2: RLZ MP |
|---|---|---|---|---|---|
| Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods | 0 | 0 | 0 | 0 | 0 |
Medication errors were defined as an unintended failure in the drug treatment process that leads to, or has the potential to lead to, harm to the study participant. Medication Errors associated with adverse reactions during the 2 Self-administration Periods were measured.
| percentage of participants | Period 1: RLZ SRD | Period 1: RLZ MP | Period 2: RLZ SRD | Period 2: RLZ MP |
|---|---|---|---|---|
| Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study | 0 | 0 | 0 | 0 |
Collected over From Week 1 up to the End of Study Visit (Week 26). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants: Training Period | 0/62 (0%) | 1/62 (1.6%) | 19/62 (30.6%) |
| Self-Administration Period 1 and 2: RLZ SRD | 0/54 (0%) | 3/54 (5.6%) | 6/54 (11.1%) |
| Self-Administration Period 1 and 2: RLZ MP | 0/53 (0%) | 1/53 (1.9%) | 6/53 (11.3%) |
| RLZ Total | 0/62 (0%) | 7/62 (11.3%) | 24/62 (38.7%) |
| Event | All Participants: Training Period | Self-Administration Period 1 and 2: RLZ SRD | Self-Administration Period 1 and 2: RLZ MP | RLZ Total |
|---|---|---|---|---|
| Myasthenia gravisNervous system disorders | 1/62 | 0/54 | 0/53 | 2/62 |
| Myocardial infarctionCardiac disorders | 0/62 | 0/54 | 1/53 | 1/62 |
| Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/62 | 1/54 | 0/53 | 1/62 |
| Transient ischaemic attackNervous system disorders | 0/62 | 1/54 | 0/53 | 1/62 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/62 | 1/54 | 0/53 | 1/62 |
| Urinary tract infectionInfections and infestations | 0/62 | 0/54 | 0/53 | 1/62 |
| Event | All Participants: Training Period | Self-Administration Period 1 and 2: RLZ SRD | Self-Administration Period 1 and 2: RLZ MP | RLZ Total |
|---|---|---|---|---|
| HeadacheNervous system disorders | 12/62 | 4/54 | 1/53 | 13/62 |
| COVID-19Infections and infestations | 4/62 | 0/54 | 1/53 | 7/62 |
| PyrexiaGeneral disorders | 4/62 | 1/54 | 3/53 | 6/62 |
| DiarrhoeaGastrointestinal disorders | 4/62 | 0/54 | 1/53 | 5/62 |
| NasopharyngitisInfections and infestations | 0/62 | 3/54 | 2/53 | 5/62 |
Baseline characteristics refers to the Safety set which included all study participants who received at least 1 dose of investigational medicinal product (IMP) (partial or full).
| Age, Continuous(years) | All Participants: Training Period |
|---|---|
| Mean | 53.3 ± 15.7 |
| Age, Customized(Participants) | All Participants: Training Period |
|---|---|
| 18 - <65 years | 45 |
| 65 - <85 years | 17 |
| >=85 years | 0 |
| Sex: Female, Male(Participants) | All Participants: Training Period |
|---|---|
| Female | 35 |
| Male | 27 |
| Race/Ethnicity, Customized(Participants) | All Participants: Training Period |
|---|---|
| Asian | 5 |
| Black or African American | 1 |
| White | 55 |
| Other/Mixed | 1 |
| Race/Ethnicity, Customized(Participants) | All Participants: Training Period |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 57 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Apr 2023 to primary completion in Apr 2024, 12 months.
Results were first posted in May 2025, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 12 months is below that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab